<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">JAMA Netw Open</journal-id><journal-id journal-id-type="iso-abbrev">JAMA Netw Open</journal-id><journal-id journal-id-type="pmc">JAMA Netw Open</journal-id><journal-title-group><journal-title>JAMA Network Open</journal-title></journal-title-group><issn pub-type="epub">2574-3805</issn><publisher><publisher-name>American Medical Association</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6739725</article-id><article-id pub-id-type="doi">10.1001/jamanetworkopen.2019.11130</article-id><article-id pub-id-type="publisher-id">zoi190436</article-id><article-categories><subj-group subj-group-type="category" specific-use="electronic"><subject>Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Investigation</subject></subj-group><subj-group subj-group-type="online-only"><subject>Online Only</subject></subj-group><subj-group subj-group-type="subject-area"><subject>Genetics and Genomics</subject></subj-group></article-categories><title-group><article-title>A Genetic Approach to the Association Between <italic>PCSK9</italic> and Sepsis</article-title><alt-title alt-title-type="headline">A Genetic Approach to the Association Between <italic>PCSK9</italic> and Sepsis</alt-title><alt-title alt-title-type="running-head">A Genetic Approach to the Association Between <italic>PCSK9</italic> and Sepsis</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Feng</surname><given-names>QiPing</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="zoi190436aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Wei</surname><given-names>Wei-Qi</given-names></name><degrees>MD</degrees><degrees>PhD</degrees><xref ref-type="aff" rid="zoi190436aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Chaugai</surname><given-names>Sandip</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="zoi190436aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Carranza Leon</surname><given-names>Barbara G.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="zoi190436aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kawai</surname><given-names>Vivian</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="zoi190436aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Carranza Leon</surname><given-names>Daniel A.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="zoi190436aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Jiang</surname><given-names>Lan</given-names></name><degrees>MS</degrees><xref ref-type="aff" rid="zoi190436aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zhong</surname><given-names>Xue</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="zoi190436aff4"><sup>4</sup></xref><xref ref-type="aff" rid="zoi190436aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Ge</given-names></name><degrees>MS</degrees><xref ref-type="aff" rid="zoi190436aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ihegword</surname><given-names>Andrea</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="zoi190436aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Shaffer</surname><given-names>Christian M.</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="zoi190436aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Linton</surname><given-names>MacRae F.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="zoi190436aff6"><sup>6</sup></xref><xref ref-type="aff" rid="zoi190436aff7"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Chung</surname><given-names>Cecilia P.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="zoi190436aff1"><sup>1</sup></xref><xref ref-type="aff" rid="zoi190436aff8"><sup>8</sup></xref></contrib><contrib contrib-type="author"><name><surname>Stein</surname><given-names>C. Michael</given-names></name><degrees>MB</degrees><degrees>ChB</degrees><xref ref-type="aff" rid="zoi190436aff1"><sup>1</sup></xref><xref ref-type="aff" rid="zoi190436aff6"><sup>6</sup></xref></contrib></contrib-group><aff id="zoi190436aff1"><label>1</label>Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee</aff><aff id="zoi190436aff2"><label>2</label>Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee</aff><aff id="zoi190436aff3"><label>3</label>Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee</aff><aff id="zoi190436aff4"><label>4</label>Division of Genetic Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee</aff><aff id="zoi190436aff5"><label>5</label>Vanderbilt Genetic Institute, Vanderbilt University, Nashville, Tennessee</aff><aff id="zoi190436aff6"><label>6</label>Department of Pharmacology, Vanderbilt University, Nashville, Tennessee</aff><aff id="zoi190436aff7"><label>7</label>Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee</aff><aff id="zoi190436aff8"><label>8</label>Division of Rheumatology and Immunology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee</aff><author-notes><title>Article Information</title><p><bold>Accepted for Publication:</bold> July 23, 2019.</p><p content-type="published-online"><bold>Published:</bold> September 11, 2019. <?xpp bx;1?>doi:<uri content-type="doi">10.1001/jamanetworkopen.2019.11130</uri></p><p content-type="open-access-note"><bold>Open Access:</bold> This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://jamanetwork.com/journals/jamanetworkopen/pages/instructions-for-authors#SecOpenAccess">CC-BY License</ext-link>. &#x000a9; 2019 Feng Q et al. <italic>JAMA Network Open</italic>.</p><corresp id="zoi190436cor1"><bold>Corresponding Author:</bold> QiPing Feng, PhD, Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, 536 Robinson Research Bldg, Vanderbilt University Medical Center, 2222 Pierce Ave, Nashville, TN 37232 (<email xlink:href="qiping.feng@vumc.org">qiping.feng@vumc.org</email>).</corresp><p content-type="author-contributions"><bold>Author Contributions:</bold> Dr Feng had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.</p><p><italic>Concept and design:</italic> Feng, Wei, Linton, Chung, Stein.</p><p><italic>Acquisition, analysis, or interpretation of data:</italic> All authors.</p><p><italic>Drafting of the manuscript:</italic> Feng, Wei, Stein.</p><p><italic>Critical revision of the manuscript for important intellectual content:</italic> All authors.</p><p><italic>Statistical analysis:</italic> Feng, Wei, Chaugai, Jiang, Zhong, Liu, Shaffer.</p><p><italic>Obtained funding:</italic> Feng, Wei, Linton.</p><p><italic>Administrative, technical, or material support:</italic> Feng, Wei, Kawai, D. A. Carranza Leon, Zhong, Liu, Linton.</p><p><italic>Supervision:</italic> Feng, Wei, Chung, Stein.</p><p content-type="COI-statement"><bold>Conflict of Interest Disclosures:</bold> Dr Kawai reported receiving grants from the National Institute of General Medical Sciences (NIGMS) during the conduct of the study and outside the submitted work. Dr Linton reported receiving grants from the National Institutes of Health (NIH) during the conduct of the study and grants from Regenron/Sanofi and Amgen, Inc, outside the submitted work. Dr Stein reported receiving grants from the NIH during the conduct of the study. No other disclosures were reported.</p><p content-type="funding-statement"><bold>Funding/Support:</bold> This study was supported by grants GM120523, GM109145, HL133786, R01GM126535, K23AR064768, K23GM117395, and 1U01HG009086-VUMC59066 from the National Human Genome Research Institute (NHGRI); by the Rheumatology Research Foundation (K-supplement); grants 16SDG27490014 and 15MCPRP25620006 from the American Heart Association; and the Vanderbilt Faculty Research Scholar Fund. The data set used for the analyses was obtained from Vanderbilt University Medical Center's resources, BioVU and the Synthetic Derivative, which are supported by institutional funding, the 1S10RR025141 instrumentation award, and by the Vanderbilt National Center for Advancing Translational Science grant UL1TR000445 from National Center for Advancing Translational Sciences, NIH. Existing genotypes in BioVU were funded by grants RC2GM092618 from NIGMS/Office of the Director, NIH, and U01HG004603 from NHGRI, NIGMS. Expert technical support was provided by the Vanderbilt Technologies for Advanced Genomics (VANTAGE) and Vanderbilt Technologies for Advanced Genomics Analysis and Research Design (VANGARD) core facilities, supported in part by grant P30 CA068485 from the Vanderbilt-Ingram Cancer Center and grant P30EY08126 from the Vanderbilt Vision Center.</p><p><bold>Role of the Funder/Sponsor:</bold> The funders had no role in design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and the decision to submit the manuscript for publication.</p></author-notes><pub-date pub-type="epub" iso-8601-date="2019-09-11T10:00"><day>11</day><month>9</month><year>2019</year></pub-date><pub-date pub-type="collection"><month>9</month><year>2019</year></pub-date><pub-date pub-type="pmc-release"><day>11</day><month>9</month><year>2019</year></pub-date><!-- PMC Release delay is 0 months and
						0 days and was based on the <pub-date
						pub-type="epub"/>. --><volume>2</volume><issue>9</issue><elocation-id>e1911130</elocation-id><history><date date-type="received"><day>29</day><month>5</month><year>2019</year></date><date date-type="accepted"><day>23</day><month>7</month><year>2019</year></date></history><permissions><copyright-statement>Copyright 2019 Feng Q et al. <italic>JAMA Network Open</italic>.</copyright-statement><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the CC-BY License.</license-p></license></permissions><self-uri content-type="pdf-version" xlink:href="jamanetwopen-2-e1911130.pdf">jamanetwopen-2-e1911130.pdf</self-uri><self-uri content-type="silverchair" xlink:href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2019.11130"/><abstract abstract-type="key-points"><title>Key Points</title><sec id="ab-zoi190436-1"><title>Question</title><p>In patients admitted to the hospital with serious infection, is there a significant association between <italic>PCSK9</italic> genetic variation and risk of sepsis?</p></sec><sec id="ab-zoi190436-2"><title>Findings</title><p>In this cohort study of 10 922 patients, the risk of sepsis was not significantly associated with <italic>PCSK9</italic> functional variants, <italic>PCSK9</italic> genetic risk score, or genetic estimation of <italic>PCSK9</italic> expression levels.</p></sec><sec id="ab-zoi190436-3"><title>Meaning</title><p>These findings suggest that <italic>PCSK9</italic> genetic variations are not significantly associated with the risk of sepsis in patients hospitalized with infection.</p></sec></abstract><abstract abstract-type="teaser"><p>This cohort study tests the associations between <italic>PCSK9</italic> genetic variants, a <italic>PCSK9</italic> genetic risk score, or genetically estimated <italic>PCSK9</italic> expression levels and the risk of sepsis among patients admitted to a hospital with infection.</p></abstract><abstract><sec id="ab-zoi190436-4"><title>Importance</title><p>Whether the <italic>PCSK9</italic> gene is associated with the progress from infection to sepsis is unknown to date.</p></sec><sec id="ab-zoi190436-5"><title>Objective</title><p>To test the associations between <italic>PCSK9</italic> genetic variants, a <italic>PCSK9</italic> genetic risk score (GRS), or genetically estimated <italic>PCSK9</italic> expression levels and the risk of sepsis among patients admitted to a hospital with infection.</p></sec><sec id="ab-zoi190436-6"><title>Design, Setting, and Participants</title><p>This retrospective cohort study used deidentified electronic health records to identify patients admitted to Vanderbilt University Medical Center, Nashville, Tennessee, with infection. Patients were white adults, had a code indicating infection from the <italic>International Classification of Diseases, Ninth Revision, Clinical Modification</italic>, or the <italic>International Statistical Classification of Diseases, Tenth Revision, Clinical Modification</italic>, and received an antibiotic within 1 day of hospital admission (N&#x02009;=&#x02009;61 502). Data were collected from January 1, 1993, through December 31, 2017, and analyzed from April 1, 2018, to March 16, 2019.</p></sec><sec id="ab-zoi190436-7"><title>Exposures</title><p>Four known <italic>PCSK9</italic> functional variants, a GRS for <italic>PCSK9</italic>, and genetically estimated <italic>PCSK9</italic> expression.</p></sec><sec id="ab-zoi190436-8"><title>Main Outcomes and Measures</title><p>The primary outcome was sepsis; secondary outcomes included cardiovascular failure and in-hospital death.</p></sec><sec id="ab-zoi190436-9"><title>Results</title><p>Of patients with infection, genotype information was available in 10 922 white patients for <italic>PCSK9</italic> functional variants (5628 men [51.5%]; mean [SD] age, 60.1&#x02009;[15.7] years), including 7624 patients with <italic>PCSK9</italic> GRS and 6033 patients with estimated <italic>PCSK9</italic> expression. Of these, 3391 developed sepsis, 835 developed cardiovascular failure, and 366 died during hospitalization. None of the 4 functional <italic>PCSK9</italic> variants were significantly associated with sepsis, cardiovascular failure, or in-hospital death, with or without adjustment for (1) age and sex or (2) age, sex, and Charlson-Deyo comorbidities (in model adjusted for age, sex, and comorbidities, odds ratios for any loss-of function variant were 0.96 [95% CI, 0.88-1.04] for sepsis, 1.05 [95% CI, 0.90-1.22] for cardiovascular failure, and 0.89 [95% CI, 0.72-1.11] for death). Similarly, neither the <italic>PCSK9</italic> GRS nor genetically estimated <italic>PCSK9</italic> expression were significantly associated with sepsis, cardiovascular failure, or in-hospital death in any of the analysis models. For GRS, in the full model adjusted for age, sex, and comorbidities, the odds ratios were 1.01 for sepsis (95% CI, 0.96-1.06; <italic>P</italic>&#x02009;=&#x02009;.70), 1.03 for cardiovascular failure (95% CI, 0.95-1.12; <italic>P</italic>&#x02009;=&#x02009;.48), and 1.05 for in-hospital death (95% CI, 0.92-1.19; <italic>P</italic>&#x02009;=&#x02009;.50). For genetically estimated <italic>PCSK9</italic> expression, in the full model adjusted for age, sex, and comorbidities, the odds ratios were 1.01 for sepsis (95% CI, 0.95-1.06; <italic>P</italic>&#x02009;=&#x02009;.86), 0.96 for cardiovascular failure (95% CI, 0.88-1.05; <italic>P</italic>&#x02009;=&#x02009;.41), and 0.99 for in-hospital death (95% CI, 0.87-1.14; <italic>P</italic>&#x02009;=&#x02009;.94).</p></sec><sec id="ab-zoi190436-10"><title>Conclusions and Relevance</title><p>In this study, <italic>PCSK9</italic> genetic variants were not significantly associated with risk of sepsis or the outcomes of sepsis in patients hospitalized with infection.</p></sec></abstract></article-meta></front><body><sec id="H1-1-ZOI190436"><title>Introduction</title><p>Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection<sup><xref rid="zoi190436r1" ref-type="bibr">1</xref></sup> and is present in 35% of deaths that occur in US hospitals.<sup><xref rid="zoi190436r2" ref-type="bibr">2</xref></sup> There are no specific treatments for sepsis; management consists of cardiorespiratory resuscitation and treatment of infection.<sup><xref rid="zoi190436r3" ref-type="bibr">3</xref></sup> Studies suggest that drugs that inhibit the <italic>PCSK9</italic> gene could have potential as a new treatment for sepsis.<sup><xref rid="zoi190436r4" ref-type="bibr">4</xref>,<xref rid="zoi190436r5" ref-type="bibr">5</xref>,<xref rid="zoi190436r6" ref-type="bibr">6</xref>,<xref rid="zoi190436r7" ref-type="bibr">7</xref></sup></p><p>The <italic>PCSK9</italic> gene increases low-density lipoprotein cholesterol (LDL-C) concentrations by targeting LDL receptors (LDLRs) for destruction, thereby decreasing transport of LDL into the liver and thus increasing circulating LDL-C concentrations.<sup><xref rid="zoi190436r8" ref-type="bibr">8</xref>,<xref rid="zoi190436r9" ref-type="bibr">9</xref></sup> Therefore, as expected, gain-of-function (GOF) and loss-of-function (LOF) variants in the <italic>PCSK9</italic> gene (OMIM <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/omim/?term=607786">607786</ext-link>) are associated with increased and decreased LDL-C concentrations, respectively.<sup><xref rid="zoi190436r10" ref-type="bibr">10</xref></sup> Concordant with those observations, drugs that inhibit the <italic>PCSK9</italic> gene lower LDL-C concentrations markedly.<sup><xref rid="zoi190436r11" ref-type="bibr">11</xref>,<xref rid="zoi190436r12" ref-type="bibr">12</xref>,<xref rid="zoi190436r13" ref-type="bibr">13</xref></sup> However, in addition to its role in the regulation of LDL-C concentrations, <italic>PCSK9</italic> also appears to affect the outcomes of sepsis through LDLR-mediated effects on bacterial lipids.</p><p>Toxic lipids such as lipopolysaccharide (LPS) from gram-negative bacteria and lipoteichoic acid (LTA) from gram-positive bacteria trigger many of the manifestations of sepsis such as vasodilation, increased capillary permeability, and the production of inflammatory cytokines.<sup><xref rid="zoi190436r14" ref-type="bibr">14</xref></sup> Lipopolysaccharide binds to LDL-C and is taken up via LDLRs into hepatocytes, where it does not cause cell injury or cytokine production. The <italic>PCSK9</italic> gene plays a role in detoxifying toxic bacterial lipids such as LPS<sup><xref rid="zoi190436r15" ref-type="bibr">15</xref>,<xref rid="zoi190436r16" ref-type="bibr">16</xref></sup> because it controls the number of LDLRs available.<sup><xref rid="zoi190436r14" ref-type="bibr">14</xref></sup> Thus, <italic>PCSK9</italic> could play a role in modulating responses to LPS and sepsis; several lines of evidence in animals and humans support this idea.<sup><xref rid="zoi190436r4" ref-type="bibr">4</xref>,<xref rid="zoi190436r5" ref-type="bibr">5</xref></sup></p><p>In mice, deletion of <italic>Pcsk9</italic> attenuated cytokine and physiological responses to LPS, and treatment with a <italic>PCSK9</italic> inhibitor improved survival in a model of sepsis.<sup><xref rid="zoi190436r4" ref-type="bibr">4</xref></sup> Also, in patients with septic shock, the presence of <italic>PCSK9</italic> LOF variants was associated with improved survival.<sup><xref rid="zoi190436r4" ref-type="bibr">4</xref></sup> Consequently, drugs that inhibit <italic>PCSK9</italic> are under investigation as a therapy for sepsis.<sup><xref rid="zoi190436r5" ref-type="bibr">5</xref></sup> Moreover, because sepsis represents an extreme on a continuum of illness, the effects of <italic>PCSK9</italic> inhibition could be more far-reaching and may not only treat sepsis but also prevent the progression from serious infection to sepsis.</p><p>We hypothesized that <italic>PCSK9</italic> LOF variants protect patients with infection from developing sepsis, and, in those who did develop sepsis, that <italic>PCSK9</italic> LOF variants would be associated with improved in-hospital survival. We addressed this hypothesis using 3 complementary approaches: (1) <italic>PCSK9</italic> variants previously shown to be associated with survival in patients with sepsis<sup><xref rid="zoi190436r4" ref-type="bibr">4</xref></sup>; (2) a <italic>PCSK9</italic> genetic risk score (GRS)<sup><xref rid="zoi190436r17" ref-type="bibr">17</xref></sup>; and (3) genetically determined <italic>PCSK9</italic> expression levels imputed using GTEx (the Genotype-Tissue Expression project) expression quantitative traits loci data.<sup><xref rid="zoi190436r18" ref-type="bibr">18</xref>,<xref rid="zoi190436r19" ref-type="bibr">19</xref></sup></p></sec><sec id="H1-2-ZOI190436"><title>Methods</title><sec id="H2-1-ZOI190436"><title>Data Sources</title><p>Data were obtained from BioVU, a deidentified DNA biobank, and the Synthetic Derivative, a deidentified version of the electronic health record (EHR), for patients at Vanderbilt University Medical Center (VUMC). The Synthetic Derivative contains the deidentified records of approximately 2.9 million people, and their clinical information is updated every 1 to 3 months. Information available includes diagnostic and procedure codes, demographics, clinical notes, problem lists, laboratory values, and medications. BioVU is linked to the Synthetic Derivative and contains more than 285&#x02009;000 DNA samples, of which approximately 87 000 have undergone genome-wide genotyping.<sup><xref rid="zoi190436r20" ref-type="bibr">20</xref>,<xref rid="zoi190436r21" ref-type="bibr">21</xref>,<xref rid="zoi190436r22" ref-type="bibr">22</xref></sup> BioVU accrues blood samples collected for clinical care that were otherwise scheduled to be discarded and applies a secure hash algorithm to deidentify the samples, which in part leads to a nonhuman subject designation with the institutional review board of VUMC. The program has received approval from the institutional review board of VUMC and was reviewed in detail by the federal Office for Human Research Protections, who agreed with the nonhuman subjects regulatory designation for the resource and subsequent research. From 2007 to 2014, BioVU operated under an opt-out accumulation model based on an opinion from the federal Office of Human Research Protection that discarded samples can be used for biomedical research without prospective consenting of each individual if the clinical data are deidentified. From 2015 to present, BioVU implemented a consented model, which adheres to the National Institutes of Health policy on genomic data sharing that was established in 2015. This study was approved by the VUMC institutional review board and followed the Strengthening the Reporting of Observational Studies in Epidemiology (<ext-link ext-link-type="uri" xlink:href="http://www.equator-network.org/reporting-guidelines/strobe/">STROBE</ext-link>) reporting guideline.</p></sec><sec id="H2-2-ZOI190436"><title>Cohort Identification</title><p>Data were collected from January 1, 1993, through December 31, 2017, and analyzed from April 1, 2018, to March 16, 2019. Using methods previously described in detail,<sup><xref rid="zoi190436r23" ref-type="bibr">23</xref></sup> we identified white patients 18 years and older who had been admitted to the hospital with an infection (<xref ref-type="fig" rid="zoi190436f1">Figure 1</xref>) and who had genome-wide genotyping available. The day of hospital admission was designated day 0. Infection was defined as (1) having a billing code indicating infection and (2) receiving an antibiotic within 1 day of hospital admission (ie, on day &#x02212;1, 0, or +1). The <italic>International Classification of Disease, Ninth Revision, Clinical Modification</italic> (<italic>ICD-9-CM</italic>) codes were used for cohort construction and covariates, and <italic>ICD-9-CM</italic> and the <italic>International Statistical Classification of Diseases, Tenth Revision, Clinical Modification</italic> (<italic>ICD-10-CM</italic>) codes were used for outcomes. The <italic>ICD-9-CM</italic> codes for infection were based on the criteria of Angus and colleagues<sup><xref rid="zoi190436r24" ref-type="bibr">24</xref></sup> and Donnelly and colleagues,<sup><xref rid="zoi190436r25" ref-type="bibr">25</xref></sup> excluding nonbacterial infections.<sup><xref rid="zoi190436r23" ref-type="bibr">23</xref></sup> If more than 1 qualifying episode of infection was present in a patient&#x02019;s EHR, only the first was included.</p><fig id="zoi190436f1" fig-type="figure" orientation="portrait" position="float"><label>Figure 1. </label><caption><title>Study Design</title><p>EHR indicates electronic health record; GRS, genetic risk score; SNP, single-nucleotide polymorphism; and VUMC, Vanderbilt University Medical Center.</p></caption><graphic xlink:href="jamanetwopen-2-e1911130-g001"/></fig></sec><sec id="H2-3-ZOI190436"><title>Outcomes</title><p>The primary outcome was sepsis defined using the Third International Consensus Definitions for Sepsis of concurrent infection and organ dysfunction<sup><xref rid="zoi190436r25" ref-type="bibr">25</xref></sup> and identified with a validated algorithm<sup><xref rid="zoi190436r2" ref-type="bibr">2</xref></sup> (with minor modifications<sup><xref rid="zoi190436r23" ref-type="bibr">23</xref></sup>) that uses billing codes and clinical variables to identify sepsis in the EHR (eFigure and eMethods in the <xref ref-type="supplementary-material" rid="note-ZOI190436-1-s">Supplement</xref>). The algorithm is highly specific (98%) and moderately sensitive (70%).<sup><xref rid="zoi190436r2" ref-type="bibr">2</xref></sup> Most cases of sepsis are present on admission to the hospital<sup><xref rid="zoi190436r2" ref-type="bibr">2</xref></sup>; therefore, to minimize the confounding effects of sepsis occurring secondary to procedures or events while in the hospital, we studied sepsis occurring within 1 day of hospital admission (days &#x02212;1, 0, and +1). Individuals with infection met the definition of sepsis if they had septic shock or severe sepsis or met any organ dysfunction criterion.<sup><xref rid="zoi190436r2" ref-type="bibr">2</xref>,<xref rid="zoi190436r23" ref-type="bibr">23</xref></sup> Septic shock and severe sepsis were defined by <italic>ICD-10-CM</italic> codes that are highly specific (99%).<sup><xref rid="zoi190436r2" ref-type="bibr">2</xref></sup> The following criteria were used to define organ dysfunction<sup><xref rid="zoi190436r23" ref-type="bibr">23</xref></sup>: (1) cardiovascular failure as use of the vasopressor norepinephrine bitartrate (Levophed) or the vasopressors dobutamine hydrochloride or dopamine hydrochloride and a billing code for administration of a vasopressor; (2) respiratory failure as use of codes for ventilation and admission to the intensive care unit; (3) renal failure as doubling or greater increase of baseline creatinine concentration (defined as the lowest creatinine concentration from 1 year before admission to hospital discharge); (4) hepatic failure as total bilirubin level of at least 2.0 mg/dL (to convert to micromoles per liter, multiply by 17.104) and doubled from baseline (the baseline value was defined as the lowest total bilirubin level occurring from 1 year before admission to hospital discharge); and (5) hematologic failure as platelet count of less than 100&#x02009;&#x000d7;&#x02009;10<sup>3</sup>/&#x003bc;L&#x02009;(to convert to &#x000d7;10<sup>9</sup> per liter, multiply by 1.0) and at least 50% decline from a baseline that must have been at least 100&#x02009;&#x000d7;&#x02009;10<sup>3</sup>/&#x003bc;L (the baseline value was defined as the highest platelet count occurring from 1 year before admission to hospital discharge). We also identified 2 secondary outcomes for exploratory purposes: cardiovascular failure as defined for the primary outcome (ie, requiring vasopressors) and in-hospital mortality. In-hospital death was extracted from discharge notes and death summaries. Event counts are summarized in eTable 1 and eTable 2 in the <xref ref-type="supplementary-material" rid="note-ZOI190436-1-s">Supplement</xref>.</p></sec><sec id="H2-4-ZOI190436"><title>Covariates</title><p>Covariates, including age and sex, were extracted from the EHR. Age was ascertained at the time of the index hospital admission. We also established the presence or absence of the comorbidities that constitute the Charlson-Deyo Comorbidity Index.<sup><xref rid="zoi190436r26" ref-type="bibr">26</xref>,<xref rid="zoi190436r27" ref-type="bibr">27</xref>,<xref rid="zoi190436r28" ref-type="bibr">28</xref></sup> We also calculated 6 principal components for ancestry using SNPRelate, version 1.16.0 (Bioconductor). For each patient, relevant diagnostic comorbidity codes occurring in the year before the index hospital admission were grouped into PheCodes<sup><xref rid="zoi190436r28" ref-type="bibr">28</xref></sup> using the R PheWAS package.<sup><xref rid="zoi190436r29" ref-type="bibr">29</xref></sup> The PheCodes were further grouped into 16 Charlson-Deyo comorbidity categories, with the categories of diabetes and diabetes with complications combined into a single diabetes variable.<sup><xref rid="zoi190436r23" ref-type="bibr">23</xref></sup> We previously performed a manual review of the performance of the sepsis criteria in 50 random EHRs. All patients met the inclusion and exclusion criteria, and the algorithms performed well.<sup><xref rid="zoi190436r23" ref-type="bibr">23</xref></sup></p></sec><sec id="H2-5-ZOI190436"><title>Functional <italic>PCSK9</italic> Gene Variants and the <italic>PCSK9</italic> GRS</title><p>We used the following 3 approaches to examine the association between <italic>PCSK9</italic> gene variants and sepsis: (1) 4 <italic>PCSK9</italic> functional variants previously shown to affect survival in patients with sepsis<sup><xref rid="zoi190436r4" ref-type="bibr">4</xref></sup>; (2) a <italic>PCSK9</italic> GRS previously shown to detect an association with risk of cardiovascular events and diabetes<sup><xref rid="zoi190436r30" ref-type="bibr">30</xref></sup>; and (3) GTEx data to estimate genetic expression of <italic>PCSK9</italic>.<sup><xref rid="zoi190436r19" ref-type="bibr">19</xref></sup> Four <italic>PCSK9</italic> single-nucleotide polymorphisms (SNPs) were previously associated with sepsis outcomes<sup><xref rid="zoi190436r4" ref-type="bibr">4</xref></sup>: <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp/505151">rs505151</ext-link> is a GOF variant, and the remainders, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp/11591147">rs11591147</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp/11583680">rs11583680</ext-link>, and <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp/562556">rs562556</ext-link>, are reduced function (termed LOF) variants. Genotypes for these <italic>PCSK9</italic> variants were extracted for 10 922 individuals who underwent genotyping on ExomeChip or genome-wide genotype platforms with imputation through the Michigan Imputation server<sup><xref rid="zoi190436r31" ref-type="bibr">31</xref></sup> with minimac3, using the Haplotype Reference Consortium reference panel, version r1.1.<sup><xref rid="zoi190436r32" ref-type="bibr">32</xref>,<xref rid="zoi190436r33" ref-type="bibr">33</xref></sup></p><p>We constructed the <italic>PCSK9</italic> GRS using the method established by Ference et al<sup><xref rid="zoi190436r30" ref-type="bibr">30</xref></sup> with a minor modification. Ference et al<sup><xref rid="zoi190436r30" ref-type="bibr">30</xref></sup> constructed a <italic>PCSK9</italic> GRS with 7 SNPs (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp/11206510">rs11206510</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp/2479409">rs2479409</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp/2149041">rs2149041</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp/2479394">rs2479394</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp/10888897">rs10888897</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp/7552841">rs7552841</ext-link>, and <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp/562556">rs562556</ext-link>); however, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp/2479409">rs2479409</ext-link> and <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp/2149041">rs2149041</ext-link> were moderately correlated (<italic>R</italic><sup>2</sup>&#x02009;&#x0003e;&#x02009;0.3) in our cohort. Therefore, as others who have constructed <italic>PCSK9</italic> risk scores have also done,<sup><xref rid="zoi190436r34" ref-type="bibr">34</xref></sup> we removed <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp/2149041">rs2149041</ext-link> and constructed a weighted 6-SNP GRS using the estimated effect size for each SNP as determined by the Global Lipids Genetics Consortium (eTable 4 in the <xref ref-type="supplementary-material" rid="note-ZOI190436-1-s">Supplement</xref>).<sup><xref rid="zoi190436r35" ref-type="bibr">35</xref>,<xref rid="zoi190436r36" ref-type="bibr">36</xref></sup></p><p>Expression of <italic>PCSK9</italic> in liver was imputed for individuals based on their genotypes using the expression predictors previously trained on the GTEx V6p release of RNA sequencing data (eTable 5 in the <xref ref-type="supplementary-material" rid="note-ZOI190436-1-s">Supplement</xref>).<sup><xref rid="zoi190436r19" ref-type="bibr">19</xref></sup> We tested the associations between median measured LDL-C levels and (1) 4 functional <italic>PCSK9</italic> variants, (2) <italic>PCSK9</italic> GRS, and (3) estimated <italic>PCSK9</italic> expression (eTables 6-8 in the <xref ref-type="supplementary-material" rid="note-ZOI190436-1-s">Supplement</xref>).</p></sec><sec id="H2-6-ZOI190436"><title>Statistical Analysis</title><p>We used logistic regression to test the associations between <italic>PCSK9</italic> (4 functional variants, GRS, and genetically determined expression levels) and outcomes (sepsis, in-hospital death, and risk of cardiovascular failure). Concordant with analyses performed by others<sup><xref rid="zoi190436r4" ref-type="bibr">4</xref></sup> for the 4-SNP analysis, we also examined outcomes in the group of patients who carried any LOF variant. We used an additive model for single-variant association analysis and estimated odds ratios (ORs) and 95% CIs per 1-SD increase for the association between the <italic>PCSK9</italic> GRS or <italic>PCSK9</italic> expression levels and outcomes. All analyses were adjusted for (1) age and sex or (2) age, sex, and comorbidities. Models were adjusted for each comorbidity category individually because each category is likely to contribute to sepsis risk differently. To determine the association between comorbidity and outcomes, we constructed a single comorbidity score for each individual and tested the associations between this score and outcomes. Analyses were performed using PLINK, version 1.9,<sup><xref rid="zoi190436r37" ref-type="bibr">37</xref></sup> and R, version 3.4.4 (R Project for Statistical Computing). We conducted power calculation using principal component software (eMethods in the <xref ref-type="supplementary-material" rid="note-ZOI190436-1-s">Supplement</xref>).<sup><xref rid="zoi190436r38" ref-type="bibr">38</xref></sup> The primary outcome was sepsis studied in 3 ways: (1) 4 functional <italic>PCSK9</italic> variants, (2) <italic>PCSK9</italic> GRS, and (3) genetically estimated <italic>PCSK9</italic> expression; thus, 2-sided <italic>P</italic>&#x02009;&#x0003c;&#x02009;.0167 was considered statistically significant. Secondary outcomes and other analyses were regarded as exploratory.</p></sec></sec><sec id="H1-3-ZOI190436"><title>Results</title><p>A total of 61 502 patients met the definition of infection, of whom 10 922 white adults (5294 women [48.5%] and 5628 men [51.5%]; mean [SD] age, 60.1&#x02009;[15.7] years) had genotypes available for the <italic>PCSK9</italic> functional variants (<xref rid="zoi190436t1" ref-type="table">Table 1</xref>); of these, 3391 developed sepsis, 835 developed cardiovascular failure, and 366 died during hospitalization. Mean (SD) duration of hospitalization was 7.5&#x02009;(9.1) days. The comorbidity score was associated with the outcomes of (1) sepsis (OR, 1.27; 95% CI, 1.26-1.29; <italic>P</italic>&#x02009;&#x0003c;&#x02009;2&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;16</sup>); (2) cardiovascular failure (OR, 1.29; 95% CI, 1.26-1.31; <italic>P</italic>&#x02009;&#x0003c;&#x02009;2&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;16</sup>); and (3) in-hospital death (OR, 1.39; 95% CI, 1.37-1.42; <italic>P</italic>&#x02009;&#x0003c;&#x02009;2&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;16</sup>) (eTable 3 in the <xref ref-type="supplementary-material" rid="note-ZOI190436-1-s">Supplement</xref>).</p><table-wrap id="zoi190436t1" orientation="portrait" position="float"><label>Table 1. </label><caption><title>Demographic Characteristics of Patients With Infection and Genotyping</title></caption><table frame="hsides" rules="groups"><col width="80.47%" span="1"/><col width="19.53%" span="1"/><thead><tr><th valign="middle" align="left" scope="col" rowspan="1" colspan="1">Characteristic</th><th valign="middle" align="left" scope="col" rowspan="1" colspan="1">Patient Data (n&#x02009;=&#x02009;10 922)</th></tr></thead><tbody><tr><td valign="middle" align="left" scope="col" rowspan="1" colspan="1">Sex, No. (%)</td><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1"> Female</td><td valign="middle" align="left" rowspan="1" colspan="1">5294 (48.5)</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1"> Male</td><td valign="middle" align="left" rowspan="1" colspan="1">5628 (51.5)</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">Age, mean (SD), y</td><td valign="middle" align="left" rowspan="1" colspan="1">60.1 (15.7)</td></tr><tr><td valign="middle" align="left" scope="col" rowspan="1" colspan="1">Comorbidities in the year preceding hospital admission, No. (%)</td><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1"> Diabetes</td><td valign="middle" align="left" rowspan="1" colspan="1">3274 (30.0)</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1"> Any malignant neoplasm, including lymphoma and leukemia, except malignant neoplasm of skin</td><td valign="middle" align="left" rowspan="1" colspan="1">2831 (25.9)</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1"> Chronic pulmonary disease</td><td valign="middle" align="left" rowspan="1" colspan="1">2694 (24.7)</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1"> Congestive heart failure</td><td valign="middle" align="left" rowspan="1" colspan="1">2185 (20.0)</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1"> Cerebrovascular disease</td><td valign="middle" align="left" rowspan="1" colspan="1">1741 (15.9)</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1"> Metastatic solid tumor</td><td valign="middle" align="left" rowspan="1" colspan="1">1665 (15.2)</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1"> Myocardial infarction</td><td valign="middle" align="left" rowspan="1" colspan="1">1464 (13.4)</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1"> Peripheral vascular disease</td><td valign="middle" align="left" rowspan="1" colspan="1">952 (8.7)</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1"> Mild liver disease</td><td valign="middle" align="left" rowspan="1" colspan="1">867 (7.9)</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1"> Renal disease</td><td valign="middle" align="left" rowspan="1" colspan="1">820 (7.5)</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1"> Moderate or severe liver disease</td><td valign="middle" align="left" rowspan="1" colspan="1">787 (7.2)</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1"> Rheumatic disease</td><td valign="middle" align="left" rowspan="1" colspan="1">674 (6.2)</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1"> Peptic ulcer disease</td><td valign="middle" align="left" rowspan="1" colspan="1">401 (3.7)</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1"> Hemiplegia or paraplegia</td><td valign="middle" align="left" rowspan="1" colspan="1">301 (2.8)</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1"> Dementia</td><td valign="middle" align="left" rowspan="1" colspan="1">268 (2.5)</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1"> AIDS/HIV</td><td valign="middle" align="left" rowspan="1" colspan="1">133 (1.2)</td></tr></tbody></table></table-wrap><sec id="H2-7-ZOI190436"><title><italic>PCSK9</italic> Functional Gene Variants and Outcomes</title><p>None of the 4 functional <italic>PCSK9</italic> gene variants were significantly associated with sepsis, cardiovascular failure, or in-hospital death (<xref ref-type="fig" rid="zoi190436f2">Figure 2</xref> and eTable 9 in the <xref ref-type="supplementary-material" rid="note-ZOI190436-1-s">Supplement</xref>) with or without adjustment for (1) age and sex or (2) age, sex, and comorbidities (in model adjusted for age, sex, and comorbidities, odds ratios for any loss-of function variant were 0.96 [95% CI, 0.88-1.04] for sepsis, 1.05 [95% CI, 0.90-1.22] for cardiovascular failure, and 0.89 [95% CI, 0.72-1.11] for death) (eTable 9 in the <xref ref-type="supplementary-material" rid="note-ZOI190436-1-s">Supplement</xref>). The group of patients who carried any LOF variant (n&#x02009;=&#x02009;4965) did not have outcomes that differed significantly from noncarriers (<xref ref-type="fig" rid="zoi190436f2">Figure 2</xref>).</p><fig id="zoi190436f2" fig-type="figure" orientation="portrait" position="float"><label>Figure 2. </label><caption><title>Associations Between <italic>PCSK9</italic> Cohorts and Sepsis Outcomes</title><p>Outcomes include sepsis, cardiovascular failure, and in-hospital death. A, Associations between <italic>PCSK9</italic> functional gene variants and outcomes are adjusted for age, sex, and comorbidities. B and C, Associations between the <italic>PCSK9</italic> genetic risk score (GRS) and estimated <italic>PCSK9</italic> expression and outcomes are stratified by tertiles and adjusted for age, sex, and comorbidities. EET indicates estimated expression tertile; LOF loss-of-function variant; OR, odds ratio.</p><p><sup>a</sup>Indicates a gain-of-function variant.</p></caption><graphic xlink:href="jamanetwopen-2-e1911130-g002"/></fig></sec><sec id="H2-8-ZOI190436"><title><italic>PCSK9</italic> GRS and Outcomes</title><p>In white patients with infection in whom genotypes were available to construct the <italic>PCSK9</italic> GRS (n&#x02009;=&#x02009;7624), the GRS was not significantly associated with sepsis, in-hospital death, or cardiovascular failure in any of the models (<xref rid="zoi190436t2" ref-type="table">Table 2</xref>). In the full model adjusted for age, sex, and comorbidities, the ORs were 1.01 for sepsis (95% CI, 0.96-1.06; <italic>P</italic>&#x02009;=&#x02009;.70), 1.03 for cardiovascular failure (95% CI, 0.95-1.12; <italic>P</italic>&#x02009;=&#x02009;.48), and 1.05 for in-hospital death (95% CI, 0.92-1.19; <italic>P</italic>&#x02009;=&#x02009;.50).</p><table-wrap id="zoi190436t2" orientation="portrait" position="float"><label>Table 2. </label><caption><title>Associations Between <italic>PCSK9</italic> Genetic Risk Score and Sepsis-Related Adverse Outcomes<xref ref-type="table-fn" rid="zoi190436t2n1"><sup>a</sup></xref></title></caption><table frame="hsides" rules="groups"><col width="16.81%" span="1"/><col width="12.89%" span="1"/><col width="7.87%" span="1"/><col width="12.98%" span="1"/><col width="7.93%" span="1"/><col width="12.89%" span="1"/><col width="7.87%" span="1"/><col width="12.89%" span="1"/><col width="7.87%" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Phenotype</th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Unadjusted</th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Adjusted for Age and Sex</th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Adjusted for Age, Sex, and Comorbidities</th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Adjusted for Age, Sex, Comorbidities, and 6 PCs</th></tr><tr><th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">OR (95% CI)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><italic>P</italic> Value</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">OR (95% CI)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><italic>P</italic> Value</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">OR (95% CI)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><italic>P</italic> Value</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">OR (95% CI)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><italic>P</italic> Value</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Sepsis</td><td valign="top" align="left" rowspan="1" colspan="1">1.01 (0.96-1.06)</td><td valign="top" align="left" rowspan="1" colspan="1">.73</td><td valign="top" align="left" rowspan="1" colspan="1">1.01 (0.96-1.06)</td><td valign="top" align="left" rowspan="1" colspan="1">.79</td><td valign="top" align="left" rowspan="1" colspan="1">1.01 (0.96-1.06)</td><td valign="top" align="left" rowspan="1" colspan="1">.70</td><td valign="top" align="left" rowspan="1" colspan="1">1.01 (0.96-1.06)</td><td valign="top" align="left" rowspan="1" colspan="1">.70</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Cardiovascular failure</td><td valign="top" align="left" rowspan="1" colspan="1">1.03 (0.95-1.12)</td><td valign="top" align="left" rowspan="1" colspan="1">.49</td><td valign="top" align="left" rowspan="1" colspan="1">1.03 (0.95-1.11)</td><td valign="top" align="left" rowspan="1" colspan="1">.55</td><td valign="top" align="left" rowspan="1" colspan="1">1.03 (0.95-1.12)</td><td valign="top" align="left" rowspan="1" colspan="1">.48</td><td valign="top" align="left" rowspan="1" colspan="1">1.03 (0.95-1.12)</td><td valign="top" align="left" rowspan="1" colspan="1">.46</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">In-hospital death</td><td valign="top" align="left" rowspan="1" colspan="1">1.06 (0.93-1.20)</td><td valign="top" align="left" rowspan="1" colspan="1">.41</td><td valign="top" align="left" rowspan="1" colspan="1">1.05 (0.93-1.20)</td><td valign="top" align="left" rowspan="1" colspan="1">.43</td><td valign="top" align="left" rowspan="1" colspan="1">1.05 (0.92-1.19)</td><td valign="top" align="left" rowspan="1" colspan="1">.50</td><td valign="top" align="left" rowspan="1" colspan="1">1.05 (0.92-1.20)</td><td valign="top" align="left" rowspan="1" colspan="1">.46</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: OR, odds ratio; PCs, principal components.</p><fn id="zoi190436t2n1"><label><sup>a</sup></label><p>Includes 7624 patients with a genetic risk score.</p></fn></table-wrap-foot></table-wrap></sec><sec id="H2-9-ZOI190436"><title>Genetically Estimated <italic>PCSK9</italic> Expression Levels and Outcomes</title><p>In white patients with infection in whom <italic>PCSK9</italic> expression levels could be calculated (n&#x02009;=&#x02009;6033), expression was not significantly associated with sepsis, in-hospital death, or cardiovascular failure in any of the models (<xref rid="zoi190436t3" ref-type="table">Table 3</xref>). In the full model adjusted for age, sex, and comorbidities, the ORs were 1.01 for sepsis (95% CI, 0.95-1.06; <italic>P</italic>&#x02009;=&#x02009;.86), 0.96 for cardiovascular failure (95% CI, 0.88-1.05; <italic>P</italic>&#x02009;=&#x02009;.41), and 0.99 for in-hospital death (95% CI, 0.87-1.14; <italic>P</italic>&#x02009;=&#x02009;.94).</p><table-wrap id="zoi190436t3" orientation="portrait" position="float"><label>Table 3. </label><caption><title>Associations Between Estimated <italic>PCSK9</italic> Expression and Sepsis-Related Adverse Outcomes<xref ref-type="table-fn" rid="zoi190436t3n1"><sup>a</sup></xref></title></caption><table frame="hsides" rules="groups"><col width="16.72%" span="1"/><col width="12.87%" span="1"/><col width="7.91%" span="1"/><col width="12.97%" span="1"/><col width="7.97%" span="1"/><col width="12.87%" span="1"/><col width="7.91%" span="1"/><col width="12.87%" span="1"/><col width="7.91%" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Phenotype</th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Unadjusted</th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Adjusted for Age and Sex</th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Adjusted for Age, Sex, and Comorbidities</th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Adjusted for Age, Sex, Comorbidities, and 6 PCs</th></tr><tr><th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">OR (95% CI)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><italic>P</italic> Value</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">OR (95% CI)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><italic>P</italic> Value</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">OR (95% CI)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><italic>P</italic> Value</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">OR (95% CI)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><italic>P</italic> Value</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Sepsis</td><td valign="top" align="left" rowspan="1" colspan="1">1.01 (0.95-1.06)</td><td valign="top" align="left" rowspan="1" colspan="1">.83</td><td valign="top" align="left" rowspan="1" colspan="1">1.01 (0.96-1.06)</td><td valign="top" align="left" rowspan="1" colspan="1">.76</td><td valign="top" align="left" rowspan="1" colspan="1">1.01 (0.95-1.06)</td><td valign="top" align="left" rowspan="1" colspan="1">.86</td><td valign="top" align="left" rowspan="1" colspan="1">1.01 (0.95-1.06)</td><td valign="top" align="left" rowspan="1" colspan="1">.85</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Cardiovascular failure</td><td valign="top" align="left" rowspan="1" colspan="1">0.97 (0.89-1.06)</td><td valign="top" align="left" rowspan="1" colspan="1">.47</td><td valign="top" align="left" rowspan="1" colspan="1">0.97 (0.89-1.06)</td><td valign="top" align="left" rowspan="1" colspan="1">.51</td><td valign="top" align="left" rowspan="1" colspan="1">0.96 (0.88-1.05)</td><td valign="top" align="left" rowspan="1" colspan="1">.41</td><td valign="top" align="left" rowspan="1" colspan="1">0.96 (0.88-1.05)</td><td valign="top" align="left" rowspan="1" colspan="1">.41</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">In-hospital death</td><td valign="top" align="left" rowspan="1" colspan="1">1.01 (0.88-1.15)</td><td valign="top" align="left" rowspan="1" colspan="1">.94</td><td valign="top" align="left" rowspan="1" colspan="1">1.00 (0.87-1.15)</td><td valign="top" align="left" rowspan="1" colspan="1">.96</td><td valign="top" align="left" rowspan="1" colspan="1">0.99 (0.87-1.14)</td><td valign="top" align="left" rowspan="1" colspan="1">.94</td><td valign="top" align="left" rowspan="1" colspan="1">1.00 (0.87-1.15)</td><td valign="top" align="left" rowspan="1" colspan="1">.99</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: OR, odds ratio; PCs, principal components.</p><fn id="zoi190436t3n1"><label><sup>a</sup></label><p>Includes 6033 patients with estimated <italic>PCSK9</italic> expression.</p></fn></table-wrap-foot></table-wrap><p>For illustrative purposes, we show the risk of sepsis, in-hospital mortality, and risk of cardiovascular failure within different tertiles (low, middle, and high) of the <italic>PCSK9</italic> GRS and genetically estimated <italic>PCSK9</italic> expression levels. Compared with those in the highest tertile, patients in the low or middle tertiles of the <italic>PCSK9</italic> GRS (<xref ref-type="fig" rid="zoi190436f2">Figure 2</xref> and eTable 10 in the <xref ref-type="supplementary-material" rid="note-ZOI190436-1-s">Supplement</xref>) and of genetically estimated <italic>PCSK9</italic> expression levels (<xref ref-type="fig" rid="zoi190436f2">Figure 2</xref> and eTable 11 in the <xref ref-type="supplementary-material" rid="note-ZOI190436-1-s">Supplement</xref>) had a similar risk of sepsis, cardiovascular failure, and in-hospital mortality, except that the middle tertile of genetically estimated <italic>PCSK9</italic> expression had a higher risk of cardiovascular failure at a nominal level of significance (OR, 1.26; 95% CI, 1.01-1.58; <italic>P</italic>&#x02009;=&#x02009;.04).</p></sec></sec><sec id="H1-4-ZOI190436"><title>Discussion</title><p>The major finding of this study is that variants in the <italic>PCSK9</italic> gene and estimated expression of <italic>PCSK9</italic> were not associated with the risk of developing sepsis or the risk of poorer outcomes in patients admitted to hospital with infection. Low-density lipoprotein, through its ability to bind LPS and other toxic bacterial lipids, attenuated the severity of sepsis in animal studies.<sup><xref rid="zoi190436r14" ref-type="bibr">14</xref></sup> Low-density lipoprotein and its LPS cargo are internalized via LDLRs into hepatocytes, thus preventing the cellular and systemic toxic effects associated with LPS.<sup><xref rid="zoi190436r14" ref-type="bibr">14</xref></sup> Accordingly, because <italic>PCSK9</italic> increases degradation of LDLRs, it decreases LPS uptake into the hepatocytes<sup><xref rid="zoi190436r4" ref-type="bibr">4</xref>,<xref rid="zoi190436r39" ref-type="bibr">39</xref></sup>; thus, strategies that target the <italic>PCSK9</italic> gene would be expected to attenuate the toxic effects of LPS and sepsis. Indeed, 2 studies in animal models support this idea.<sup><xref rid="zoi190436r4" ref-type="bibr">4</xref>,<xref rid="zoi190436r40" ref-type="bibr">40</xref></sup></p><p>Mice with a deletion of <italic>Pcsk9</italic> had decreased production of interleukin-6 and other inflammatory cytokines compared with control animals after they received intraperitoneal LPS; they also had attenuated physiological responses to LPS with greater preservation of mean arterial pressure and ejection fraction.<sup><xref rid="zoi190436r4" ref-type="bibr">4</xref></sup> In another murine model of sepsis, <italic>Pcsk9</italic> overexpression was associated with increased bacterial dissemination, inflammation, and histopathological damage compared with control animals, whereas mice with deletion of <italic>Pcsk9</italic> were protected against these effects.<sup><xref rid="zoi190436r40" ref-type="bibr">40</xref></sup></p><p>Pharmacological inhibition of <italic>PCSK9</italic> also protected against the effects of sepsis in mice; an antibody that blocked <italic>PCSK9</italic> blunted inflammatory cytokines and improved survival in a polymicrobial peritonitis model.<sup><xref rid="zoi190436r4" ref-type="bibr">4</xref></sup> These beneficial effects were absent when the gene for the LDLR was deleted, indicating that <italic>PCSK9</italic> inhibition altered responses to LPS through the LDLR.<sup><xref rid="zoi190436r4" ref-type="bibr">4</xref></sup> However, in a second study, neither <italic>Pcsk9</italic> deletion nor <italic>PCSK9</italic> antibodies protected mice against LPS-induced mortality.<sup><xref rid="zoi190436r41" ref-type="bibr">41</xref></sup></p><p>Less information is available to date about <italic>PCSK9</italic> and its association with LPS clearance and sepsis in humans. Previous observations<sup><xref rid="zoi190436r23" ref-type="bibr">23</xref>,<xref rid="zoi190436r42" ref-type="bibr">42</xref></sup> found that levels of LDL-C do not appear to be directly associated with the risk of sepsis in patients with infection. In healthy participants, peak and area-under-the-curve of interleukin 6 response to an intravenous injection of LPS were attenuated in those who carried a <italic>PCSK9</italic> LOF allele compared with those who did not.<sup><xref rid="zoi190436r4" ref-type="bibr">4</xref></sup> In patients with sepsis, plasma <italic>PCSK9</italic> concentrations were elevated compared with those without sepsis and were associated with decreased clearance of endotoxin.<sup><xref rid="zoi190436r43" ref-type="bibr">43</xref></sup> Moreover, in 2 cohorts of patients with septic shock, Walley and colleagues<sup><xref rid="zoi190436r4" ref-type="bibr">4</xref>,<xref rid="zoi190436r42" ref-type="bibr">42</xref></sup> reported that the groups that carried any of 3 <italic>PCSK9</italic> LOF variants had improved survival compared with the groups with no variants or a GOF variant. Conversely, groups with a GOF variant had worse survival than those with no variants or an LOF variant.<sup><xref rid="zoi190436r4" ref-type="bibr">4</xref></sup></p><p>Because sepsis is a continuum of severe illness after infection, and because studies in animals showed that <italic>PCSK9</italic> was associated with not only survival after sepsis but also bacterial dissemination and physiological responses to LPS and infection,<sup><xref rid="zoi190436r4" ref-type="bibr">4</xref>,<xref rid="zoi190436r40" ref-type="bibr">40</xref></sup> we hypothesized that <italic>PCSK9</italic> decreased-function genetic variants would be associated with a lower risk of progression from infection to sepsis. We used 3 approaches. First, we studied the same 4 variants that were previously associated with altered survival in patients with septic shock.<sup><xref rid="zoi190436r4" ref-type="bibr">4</xref></sup> Second, we used a <italic>PCSK9</italic> GRS (derived from the effect of variants on LDL-C levels) that previously detected associations between <italic>PCSK9</italic> and risk of cardiovascular events and diabetes.<sup><xref rid="zoi190436r30" ref-type="bibr">30</xref></sup> Third, we estimated genetic <italic>PCSK9</italic> expression levels using GTEx information. The 3 approaches yielded concordant results: <italic>PCSK9</italic> variants were not significantly associated with risk of developing sepsis in patients with infection. Similarly, these variants were not significantly associated with the other outcomes.</p><p>Our study had several differences from that of Walley and colleagues<sup><xref rid="zoi190436r4" ref-type="bibr">4</xref></sup> that may account for the different conclusions. First, their patients had septic shock and were enrolled from 2 clinical trials; second, they included several ethnic groups with statistical adjustment for ancestry; and third, the outcome was 28-day mortality. The present study included not only patients with septic shock but also those with other manifestations of sepsis. Because we included all patients with sepsis at a large tertiary care hospital who had genotype information, the characteristics of these patients differ from those enrolled in clinical trials for septic shock. For example, to better establish the progressive association between infection and sepsis, we required that sepsis occur within 1 day of hospitalization for infection. Thus, patients admitted for a surgical procedure who subsequently developed sepsis in the hospital would not be included in our study. Also, we studied only white patients to minimize the effects of population stratification on any association between genotype and outcomes; however, this is unlikely to lead to a false-negative result because the sample size was large. In-hospital mortality was a secondary outcome because it is more clearly linked with the episode of sepsis, and we found no association between carriage of <italic>PCSK9</italic> LOF or GOF variants and this outcome. Nevertheless, we cannot exclude the possibility that beneficial effects of <italic>PCSK9</italic> variants on sepsis outcomes would be observed after patients are discharged from hospital.<sup><xref rid="zoi190436r44" ref-type="bibr">44</xref></sup></p><sec id="H2-10-ZOI190436"><title>Strengths and Limitations</title><p>The study included patients who are representative of those admitted to a tertiary care hospital with infection, and the findings are therefore broadly generalizable to that population. However, we cannot exclude a potential effect of <italic>PCSK9</italic> on outcomes in patients with sepsis associated with specific causes, or those with specific manifestations of sepsis. Second, information in the EHR linked to genotypes allowed us to perform the study efficiently; however, we did not perform a randomized clinical trial. One major advantage of randomization is to minimize unequal distribution of confounding variables among groups of interest. The genetic approaches used also have this advantage because constructing groups according to genotype should be minimally affected by unequal distribution of confounders. Third, we used 3 genetic approaches: the 4-SNP approach that previously found an association with sepsis outcomes,<sup><xref rid="zoi190436r4" ref-type="bibr">4</xref></sup> a <italic>PCSK9</italic> GRS previously associated with cardiovascular outcomes,<sup><xref rid="zoi190436r30" ref-type="bibr">30</xref></sup> and genetically estimated gene expression levels.<sup><xref rid="zoi190436r19" ref-type="bibr">19</xref></sup> In BioVU, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp/11591147">rs11591147</ext-link> and <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp/505151">rs505151</ext-link> and the <italic>PCSK9</italic> GRS were significantly associated with measured LDL-C; however, estimated <italic>PCSK9</italic> expression was not (eTables 6-8 in the <xref ref-type="supplementary-material" rid="note-ZOI190436-1-s">Supplement</xref>). Protein function could be more important than variability in gene expression in regulating LDL-C levels. Furthermore, although these approaches have previously been successful in other studies, the genetic signal may have been too small to affect the outcomes, and a clinical trial of a drug that inhibits <italic>PCSK9</italic> in patients with sepsis could reach different conclusions. Fourth, we did not evaluate the association between statin use and risk of sepsis. The question is complex: higher LDL-C levels have been postulated to be protective in sepsis (although a previous study of LDL-C in sepsis<sup><xref rid="zoi190436r23" ref-type="bibr">23</xref></sup> did not support that idea), and statins, which lower LDL-C levels, have also been postulated to be beneficial in sepsis. The results have been inconclusive, and a systematic review and meta-analysis of randomized trials<sup><xref rid="zoi190436r45" ref-type="bibr">45</xref></sup> concluded that statin treatment was not associated with reduced mortality in sepsis. In addition, this study will require replication. The current algorithm included <italic>International Classification of Disease</italic> or <italic>Current Procedural Terminology</italic> codes, medications, laboratory test results, and knowledge of temporal associations; such information is not available in many databases. We believe that in the future, the algorithm can be modified and applied to other practice-based cohorts to test the generalizability of our observations.</p></sec></sec><sec id="H1-5-ZOI190436"><title>Conclusions</title><p>In this study, genetic variants of <italic>PCSK9</italic> were not significantly associated with the risk of sepsis or with the outcomes of sepsis in patients hospitalized with infection. We believe that future studies should modify the algorithm used and include practice-based cohorts.</p></sec></body><back><ref-list id="REF-ZOI190436"><title>References</title><ref id="zoi190436r1"><label>1</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Singer</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Deutschman</surname><given-names>CS</given-names></name>, <name name-style="western"><surname>Seymour</surname><given-names>CW</given-names></name>, <etal/></person-group>
<article-title>The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)</article-title>. <source>JAMA</source>. <year>2016</year>;<volume>315</volume>(<issue>8</issue>):-. doi:<pub-id pub-id-type="doi">10.1001/jama.2016.0287</pub-id>
<?supplied-pmid 26903338?><pub-id pub-id-type="pmid">26903338</pub-id></mixed-citation></ref><ref id="zoi190436r2"><label>2</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Rhee</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Dantes</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Epstein</surname><given-names>L</given-names></name>, <etal/>; <collab>CDC Prevention Epicenter Program</collab></person-group>
<article-title>Incidence and trends of sepsis in US hospitals using clinical vs claims data, 2009-2014</article-title>. <source>JAMA</source>. <year>2017</year>;<volume>318</volume>(<issue>13</issue>):<fpage>1241</fpage>-<lpage>1249</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2017.13836</pub-id>
<?supplied-pmid 28903154?><pub-id pub-id-type="pmid">28903154</pub-id></mixed-citation></ref><ref id="zoi190436r3"><label>3</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Angus</surname><given-names>DC</given-names></name>, <name name-style="western"><surname>van der Poll</surname><given-names>T</given-names></name></person-group>
<article-title>Severe sepsis and septic shock</article-title>. <source>N Engl J Med</source>. <year>2013</year>;<volume>369</volume>(<issue>9</issue>):<fpage>840</fpage>-<lpage>851</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMra1208623</pub-id>
<?supplied-pmid 23984731?><pub-id pub-id-type="pmid">23984731</pub-id></mixed-citation></ref><ref id="zoi190436r4"><label>4</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Walley</surname><given-names>KR</given-names></name>, <name name-style="western"><surname>Thain</surname><given-names>KR</given-names></name>, <name name-style="western"><surname>Russell</surname><given-names>JA</given-names></name>, <etal/></person-group>
<article-title>PCSK9 is a critical regulator of the innate immune response and septic shock outcome</article-title>. <source>Sci Transl Med</source>. <year>2014</year>;<volume>6</volume>(<issue>258</issue>):<fpage>258ra143</fpage>. doi:<pub-id pub-id-type="doi">10.1126/scitranslmed.3008782</pub-id><?supplied-pmid 25320235?><pub-id pub-id-type="pmid">25320235</pub-id></mixed-citation></ref><ref id="zoi190436r5"><label>5</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Momtazi</surname><given-names>AA</given-names></name>, <name name-style="western"><surname>Banach</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Sahebkar</surname><given-names>A</given-names></name></person-group>
<article-title>PCSK9 inhibitors in sepsis: a new potential indication?</article-title>
<source>Expert Opin Investig Drugs</source>. <year>2017</year>;<volume>26</volume>(<issue>2</issue>):<fpage>137</fpage>-<lpage>139</lpage>. doi:<pub-id pub-id-type="doi">10.1080/13543784.2017.1272570</pub-id>
<?supplied-pmid 27967260?><pub-id pub-id-type="pmid">27967260</pub-id></mixed-citation></ref><ref id="zoi190436r6"><label>6</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Paciullo</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Fallarino</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Bianconi</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Mannarino</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Sahebkar</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Pirro</surname><given-names>M</given-names></name></person-group>
<article-title>PCSK9 at the crossroad of cholesterol metabolism and immune function during infections</article-title>. <source>J Cell Physiol</source>. <year>2017</year>;<volume>232</volume>(<issue>9</issue>):<fpage>2330</fpage>-<lpage>2338</lpage>. doi:<pub-id pub-id-type="doi">10.1002/jcp.25767</pub-id>
<?supplied-pmid 28063230?><pub-id pub-id-type="pmid">28063230</pub-id></mixed-citation></ref><ref id="zoi190436r7"><label>7</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Bray</surname><given-names>N</given-names></name></person-group>
<article-title>Sepsis: PCSK9 blockade helps clear pathogenic lipids</article-title>. <source>Nat Rev Drug Discov</source>. <year>2014</year>;<volume>13</volume>(<issue>12</issue>):<fpage>886</fpage>. doi:<pub-id pub-id-type="doi">10.1038/nrd4492</pub-id>
<?supplied-pmid 25435211?><pub-id pub-id-type="pmid">25435211</pub-id></mixed-citation></ref><ref id="zoi190436r8"><label>8</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Urban</surname><given-names>D</given-names></name>, <name name-style="western"><surname>P&#x000f6;ss</surname><given-names>J</given-names></name>, <name name-style="western"><surname>B&#x000f6;hm</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Laufs</surname><given-names>U</given-names></name></person-group>
<article-title>Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis</article-title>. <source>J Am Coll Cardiol</source>. <year>2013</year>;<volume>62</volume>(<issue>16</issue>):<fpage>1401</fpage>-<lpage>1408</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jacc.2013.07.056</pub-id>
<?supplied-pmid 23973703?><pub-id pub-id-type="pmid">23973703</pub-id></mixed-citation></ref><ref id="zoi190436r9"><label>9</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Peterson</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Fong</surname><given-names>LG</given-names></name>, <name name-style="western"><surname>Young</surname><given-names>SG</given-names></name></person-group>
<article-title>PCSK9 function and physiology</article-title>. <source>J Lipid Res</source>. <year>2008</year>;<volume>49</volume>(<issue>7</issue>):<fpage>1595</fpage>-<lpage>1599</lpage>. doi:<pub-id pub-id-type="doi">10.1194/jlr.CX00001-JLR200</pub-id>
<?supplied-pmid 18663786?><pub-id pub-id-type="pmid">18663786</pub-id></mixed-citation></ref><ref id="zoi190436r10"><label>10</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Cohen</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Boerwinkle</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Mosley</surname><given-names>TH</given-names><suffix>Jr</suffix></name>, <name name-style="western"><surname>Hobbs</surname><given-names>HH</given-names></name></person-group>
<article-title>Sequence variations in PCSK9, low LDL, and protection against coronary heart disease</article-title>. <source>N Engl J Med</source>. <year>2006</year>;<volume>354</volume>(<issue>12</issue>):<fpage>1264</fpage>-<lpage>1272</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa054013</pub-id>
<?supplied-pmid 16554528?><pub-id pub-id-type="pmid">16554528</pub-id></mixed-citation></ref><ref id="zoi190436r11"><label>11</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Robinson</surname><given-names>JG</given-names></name>, <name name-style="western"><surname>Farnier</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Krempf</surname><given-names>M</given-names></name>, <etal/>; <collab>ODYSSEY LONG TERM Investigators</collab></person-group>
<article-title>Efficacy and safety of alirocumab in reducing lipids and cardiovascular events</article-title>. <source>N Engl J Med</source>. <year>2015</year>;<volume>372</volume>(<issue>16</issue>):<fpage>1489</fpage>-<lpage>1499</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa1501031</pub-id><?supplied-pmid 25773378?><pub-id pub-id-type="pmid">25773378</pub-id></mixed-citation></ref><ref id="zoi190436r12"><label>12</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Sabatine</surname><given-names>MS</given-names></name>, <name name-style="western"><surname>Giugliano</surname><given-names>RP</given-names></name>, <name name-style="western"><surname>Wiviott</surname><given-names>SD</given-names></name>, <etal/>; <collab>Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators</collab></person-group>
<article-title>Efficacy and safety of evolocumab in reducing lipids and cardiovascular events</article-title>. <source>N Engl J Med</source>. <year>2015</year>;<volume>372</volume>(<issue>16</issue>):<fpage>1500</fpage>-<lpage>1509</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa1500858</pub-id><?supplied-pmid 25773607?><pub-id pub-id-type="pmid">25773607</pub-id></mixed-citation></ref><ref id="zoi190436r13"><label>13</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Giugliano</surname><given-names>RP</given-names></name>, <name name-style="western"><surname>Pedersen</surname><given-names>TR</given-names></name>, <name name-style="western"><surname>Park</surname><given-names>JG</given-names></name>, <etal/>; <collab>FOURIER Investigators</collab></person-group>
<article-title>Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial</article-title>. <source>Lancet</source>. <year>2017</year>;<volume>390</volume>(<issue>10106</issue>):<fpage>1962</fpage>-<lpage>1971</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(17)32290-0</pub-id>
<?supplied-pmid 28859947?><pub-id pub-id-type="pmid">28859947</pub-id></mixed-citation></ref><ref id="zoi190436r14"><label>14</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Grin</surname><given-names>PM</given-names></name>, <name name-style="western"><surname>Dwivedi</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>Chathely</surname><given-names>KM</given-names></name>, <etal/></person-group>
<article-title>Low-density lipoprotein (LDL)&#x02013;dependent uptake of gram-positive lipoteichoic acid and gram-negative lipopolysaccharide occurs through LDL receptor</article-title>. <source>Sci Rep</source>. <year>2018</year>;<volume>8</volume>(<issue>1</issue>):<fpage>10496</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41598-018-28777-0</pub-id>
<?supplied-pmid 30002483?><pub-id pub-id-type="pmid">30002483</pub-id></mixed-citation></ref><ref id="zoi190436r15"><label>15</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Levels</surname><given-names>JHM</given-names></name>, <name name-style="western"><surname>Abraham</surname><given-names>PR</given-names></name>, <name name-style="western"><surname>van den Ende</surname><given-names>A</given-names></name>, <name name-style="western"><surname>van Deventer</surname><given-names>SJH</given-names></name></person-group>
<article-title>Distribution and kinetics of lipoprotein-bound endotoxin</article-title>. <source>Infect Immun</source>. <year>2001</year>;<volume>69</volume>(<issue>5</issue>):<fpage>2821</fpage>-<lpage>2828</lpage>. doi:<pub-id pub-id-type="doi">10.1128/IAI.69.5.2821-2828.2001</pub-id>
<?supplied-pmid 11292694?><pub-id pub-id-type="pmid">11292694</pub-id></mixed-citation></ref><ref id="zoi190436r16"><label>16</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Levels</surname><given-names>JHM</given-names></name>, <name name-style="western"><surname>Abraham</surname><given-names>PR</given-names></name>, <name name-style="western"><surname>van Barreveld</surname><given-names>EP</given-names></name>, <name name-style="western"><surname>Meijers</surname><given-names>JCM</given-names></name>, <name name-style="western"><surname>van Deventer</surname><given-names>SJH</given-names></name></person-group>
<article-title>Distribution and kinetics of lipoprotein-bound lipoteichoic acid</article-title>. <source>Infect Immun</source>. <year>2003</year>;<volume>71</volume>(<issue>6</issue>):<fpage>3280</fpage>-<lpage>3284</lpage>. doi:<pub-id pub-id-type="doi">10.1128/IAI.71.6.3280-3284.2003</pub-id>
<?supplied-pmid 12761109?><pub-id pub-id-type="pmid">12761109</pub-id></mixed-citation></ref><ref id="zoi190436r17"><label>17</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Ference</surname><given-names>BA</given-names></name>, <name name-style="western"><surname>Majeed</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Penumetcha</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Flack</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Brook</surname><given-names>RD</given-names></name></person-group>
<article-title>Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in <italic>NPC1L1</italic>, <italic>HMGCR</italic>, or both: a 2 &#x000d7; 2 factorial Mendelian randomization study</article-title>. <source>J Am Coll Cardiol</source>. <year>2015</year>;<volume>65</volume>(<issue>15</issue>):<fpage>1552</fpage>-<lpage>1561</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jacc.2015.02.020</pub-id>
<?supplied-pmid 25770315?><pub-id pub-id-type="pmid">25770315</pub-id></mixed-citation></ref><ref id="zoi190436r18"><label>18</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Ardlie</surname><given-names>KG</given-names></name>, <etal/>; <collab>GTEx Consortium</collab></person-group>
<article-title>Human genomics: the Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans</article-title>. <source>Science</source>. <year>2015</year>;<volume>348</volume>(<issue>6235</issue>):<fpage>648</fpage>-<lpage>660</lpage>. doi:<pub-id pub-id-type="doi">10.1126/science.1262110</pub-id>
<?supplied-pmid 25954001?><pub-id pub-id-type="pmid">25954001</pub-id></mixed-citation></ref><ref id="zoi190436r19"><label>19</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Gamazon</surname><given-names>ER</given-names></name>, <name name-style="western"><surname>Wheeler</surname><given-names>HE</given-names></name>, <name name-style="western"><surname>Shah</surname><given-names>KP</given-names></name>, <etal/>; <collab>GTEx Consortium</collab></person-group>
<article-title>A gene-based association method for mapping traits using reference transcriptome data</article-title>. <source>Nat Genet</source>. <year>2015</year>;<volume>47</volume>(<issue>9</issue>):<fpage>1091</fpage>-<lpage>1098</lpage>. doi:<pub-id pub-id-type="doi">10.1038/ng.3367</pub-id>
<?supplied-pmid 26258848?><pub-id pub-id-type="pmid">26258848</pub-id></mixed-citation></ref><ref id="zoi190436r20"><label>20</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Wei</surname><given-names>W-Q</given-names></name>, <name name-style="western"><surname>Denny</surname><given-names>JC</given-names></name></person-group>
<article-title>Extracting research-quality phenotypes from electronic health records to support precision medicine</article-title>. <source>Genome Med</source>. <year>2015</year>;<volume>7</volume>(<issue>1</issue>):<fpage>41</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s13073-015-0166-y</pub-id>
<?supplied-pmid 25937834?><pub-id pub-id-type="pmid">25937834</pub-id></mixed-citation></ref><ref id="zoi190436r21"><label>21</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Xu</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Stenner</surname><given-names>SP</given-names></name>, <name name-style="western"><surname>Doan</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Johnson</surname><given-names>KB</given-names></name>, <name name-style="western"><surname>Waitman</surname><given-names>LR</given-names></name>, <name name-style="western"><surname>Denny</surname><given-names>JC</given-names></name></person-group>
<article-title>MedEx: a medication information extraction system for clinical narratives</article-title>. <source>J Am Med Inform Assoc</source>. <year>2010</year>;<volume>17</volume>(<issue>1</issue>):<fpage>19</fpage>-<lpage>24</lpage>. doi:<pub-id pub-id-type="doi">10.1197/jamia.M3378</pub-id>
<?supplied-pmid 20064797?><pub-id pub-id-type="pmid">20064797</pub-id></mixed-citation></ref><ref id="zoi190436r22"><label>22</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Denny</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Bastarache</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Ritchie</surname><given-names>MD</given-names></name>, <etal/></person-group>
<article-title>Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data</article-title>. <source>Nat Biotechnol</source>. <year>2013</year>;<volume>31</volume>(<issue>12</issue>):<fpage>1102</fpage>-<lpage>1110</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nbt.2749</pub-id>
<?supplied-pmid 24270849?><pub-id pub-id-type="pmid">24270849</pub-id></mixed-citation></ref><ref id="zoi190436r23"><label>23</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Feng</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Wei</surname><given-names>WQ</given-names></name>, <name name-style="western"><surname>Chaugai</surname><given-names>S</given-names></name>, <etal/></person-group>
<article-title>Association between low-density lipoprotein cholesterol levels and risk for sepsis among patients admitted to the hospital with infection</article-title>. <source>JAMA Netw Open</source>. <year>2019</year>;<volume>2</volume>(<issue>1</issue>):<fpage>e187223</fpage>. doi:<pub-id pub-id-type="doi">10.1001/jamanetworkopen.2018.7223</pub-id>
<?supplied-pmid 30657536?><pub-id pub-id-type="pmid">30657536</pub-id></mixed-citation></ref><ref id="zoi190436r24"><label>24</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Angus</surname><given-names>DC</given-names></name>, <name name-style="western"><surname>Linde-Zwirble</surname><given-names>WT</given-names></name>, <name name-style="western"><surname>Lidicker</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Clermont</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Carcillo</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Pinsky</surname><given-names>MR</given-names></name></person-group>
<article-title>Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care</article-title>. <source>Crit Care Med</source>. <year>2001</year>;<volume>29</volume>(<issue>7</issue>):<fpage>1303</fpage>-<lpage>1310</lpage>. doi:<pub-id pub-id-type="doi">10.1097/00003246-200107000-00002</pub-id>
<?supplied-pmid 11445675?><pub-id pub-id-type="pmid">11445675</pub-id></mixed-citation></ref><ref id="zoi190436r25"><label>25</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Donnelly</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Safford</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>Shapiro</surname><given-names>NI</given-names></name>, <name name-style="western"><surname>Baddley</surname><given-names>JW</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>HE</given-names></name></person-group>
<article-title>Application of the Third International Consensus Definitions for Sepsis (Sepsis-3) classification: a retrospective population-based cohort study</article-title>. <source>Lancet Infect Dis</source>. <year>2017</year>;<volume>17</volume>(<issue>6</issue>):<fpage>661</fpage>-<lpage>670</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1473-3099(17)30117-2</pub-id>
<?supplied-pmid 28268067?><pub-id pub-id-type="pmid">28268067</pub-id></mixed-citation></ref><ref id="zoi190436r26"><label>26</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Deyo</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Cherkin</surname><given-names>DC</given-names></name>, <name name-style="western"><surname>Ciol</surname><given-names>MA</given-names></name></person-group>
<article-title>Adapting a clinical comorbidity index for use with <italic>ICD-9-CM</italic> administrative databases</article-title>. <source>J Clin Epidemiol</source>. <year>1992</year>;<volume>45</volume>(<issue>6</issue>):<fpage>613</fpage>-<lpage>619</lpage>. doi:<pub-id pub-id-type="doi">10.1016/0895-4356(92)90133-8</pub-id>
<?supplied-pmid 1607900?><pub-id pub-id-type="pmid">1607900</pub-id></mixed-citation></ref><ref id="zoi190436r27"><label>27</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Charlson</surname><given-names>ME</given-names></name>, <name name-style="western"><surname>Pompei</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Ales</surname><given-names>KL</given-names></name>, <name name-style="western"><surname>MacKenzie</surname><given-names>CR</given-names></name></person-group>
<article-title>A new method of classifying prognostic comorbidity in longitudinal studies: development and validation</article-title>. <source>J Chronic Dis</source>. <year>1987</year>;<volume>40</volume>(<issue>5</issue>):<fpage>373</fpage>-<lpage>383</lpage>. doi:<pub-id pub-id-type="doi">10.1016/0021-9681(87)90171-8</pub-id>
<?supplied-pmid 3558716?><pub-id pub-id-type="pmid">3558716</pub-id></mixed-citation></ref><ref id="zoi190436r28"><label>28</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Quan</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Sundararajan</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Halfon</surname><given-names>P</given-names></name>, <etal/></person-group>
<article-title>Coding algorithms for defining comorbidities in <italic>ICD-9-CM</italic> and <italic>ICD-10</italic> administrative data</article-title>. <source>Med Care</source>. <year>2005</year>;<volume>43</volume>(<issue>11</issue>):<fpage>1130</fpage>-<lpage>1139</lpage>. doi:<pub-id pub-id-type="doi">10.1097/01.mlr.0000182534.19832.83</pub-id>
<?supplied-pmid 16224307?><pub-id pub-id-type="pmid">16224307</pub-id></mixed-citation></ref><ref id="zoi190436r29"><label>29</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Carroll</surname><given-names>RJ</given-names></name>, <name name-style="western"><surname>Bastarache</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Denny</surname><given-names>JCR</given-names></name></person-group>
<article-title>R PheWAS: data analysis and plotting tools for phenome-wide association studies in the R environment</article-title>. <source>Bioinformatics</source>. <year>2014</year>;<volume>30</volume>(<issue>16</issue>):<fpage>2375</fpage>-<lpage>2376</lpage>. doi:<pub-id pub-id-type="doi">10.1093/bioinformatics/btu197</pub-id>
<?supplied-pmid 24733291?><pub-id pub-id-type="pmid">24733291</pub-id></mixed-citation></ref><ref id="zoi190436r30"><label>30</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Ference</surname><given-names>BA</given-names></name>, <name name-style="western"><surname>Robinson</surname><given-names>JG</given-names></name>, <name name-style="western"><surname>Brook</surname><given-names>RD</given-names></name>, <etal/></person-group>
<article-title>Variation in <italic>PCSK9</italic> and <italic>HMGCR</italic> and risk of cardiovascular disease and diabetes</article-title>. <source>N Engl J Med</source>. <year>2016</year>;<volume>375</volume>(<issue>22</issue>):<fpage>2144</fpage>-<lpage>2153</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa1604304</pub-id>
<?supplied-pmid 27959767?><pub-id pub-id-type="pmid">27959767</pub-id></mixed-citation></ref><ref id="zoi190436r31"><label>31</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Das</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Forer</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Sch&#x000f6;nherr</surname><given-names>S</given-names></name>, <etal/></person-group>
<article-title>Next-generation genotype imputation service and methods</article-title>. <source>Nat Genet</source>. <year>2016</year>;<volume>48</volume>(<issue>10</issue>):<fpage>1284</fpage>-<lpage>1287</lpage>. doi:<pub-id pub-id-type="doi">10.1038/ng.3656</pub-id>
<?supplied-pmid 27571263?><pub-id pub-id-type="pmid">27571263</pub-id></mixed-citation></ref><ref id="zoi190436r32"><label>32</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>McCarthy</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Das</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Kretzschmar</surname><given-names>W</given-names></name>, <etal/>; <collab>Haplotype Reference Consortium</collab></person-group>
<article-title>A reference panel of 64,976 haplotypes for genotype imputation</article-title>. <source>Nat Genet</source>. <year>2016</year>;<volume>48</volume>(<issue>10</issue>):<fpage>1279</fpage>-<lpage>1283</lpage>. doi:<pub-id pub-id-type="doi">10.1038/ng.3643</pub-id><?supplied-pmid 27548312?><pub-id pub-id-type="pmid">27548312</pub-id></mixed-citation></ref><ref id="zoi190436r33"><label>33</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Do</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Willer</surname><given-names>CJ</given-names></name>, <name name-style="western"><surname>Schmidt</surname><given-names>EM</given-names></name>, <etal/></person-group>
<article-title>Common variants associated with plasma triglycerides and risk for coronary artery disease</article-title>. <source>Nat Genet</source>. <year>2013</year>;<volume>45</volume>(<issue>11</issue>):<fpage>1345</fpage>-<lpage>1352</lpage>. doi:<pub-id pub-id-type="doi">10.1038/ng.2795</pub-id>
<?supplied-pmid 24097064?><pub-id pub-id-type="pmid">24097064</pub-id></mixed-citation></ref><ref id="zoi190436r34"><label>34</label><mixed-citation publication-type="web"><person-group><name name-style="western"><surname>Lyall</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Ward</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Banach</surname><given-names>M</given-names></name>, <etal/></person-group>
<italic>PCSK9</italic> genetic variants, life-long lowering of LDL-cholesterol and cognition: a large-scale Mendelian randomization study. BioRxiv. Preprint posted May 31, <year>2018</year>.</mixed-citation></ref><ref id="zoi190436r35"><label>35</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Willer</surname><given-names>CJ</given-names></name>, <name name-style="western"><surname>Schmidt</surname><given-names>EM</given-names></name>, <name name-style="western"><surname>Sengupta</surname><given-names>S</given-names></name>, <etal/>; <collab>Global Lipids Genetics Consortium</collab></person-group>
<article-title>Discovery and refinement of loci associated with lipid levels</article-title>. <source>Nat Genet</source>. <year>2013</year>;<volume>45</volume>(<issue>11</issue>):<fpage>1274</fpage>-<lpage>1283</lpage>. doi:<pub-id pub-id-type="doi">10.1038/ng.2797</pub-id>
<?supplied-pmid 24097068?><pub-id pub-id-type="pmid">24097068</pub-id></mixed-citation></ref><ref id="zoi190436r36"><label>36</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Teslovich</surname><given-names>TM</given-names></name>, <name name-style="western"><surname>Musunuru</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Smith</surname><given-names>AV</given-names></name>, <etal/></person-group>
<article-title>Biological, clinical and population relevance of 95 loci for blood lipids</article-title>. <source>Nature</source>. <year>2010</year>;<volume>466</volume>(<issue>7307</issue>):<fpage>707</fpage>-<lpage>713</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nature09270</pub-id>
<?supplied-pmid 20686565?><pub-id pub-id-type="pmid">20686565</pub-id></mixed-citation></ref><ref id="zoi190436r37"><label>37</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Purcell</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Neale</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Todd-Brown</surname><given-names>K</given-names></name>, <etal/></person-group>
<article-title>PLINK: a tool set for whole-genome association and population-based linkage analyses</article-title>. <source>Am J Hum Genet</source>. <year>2007</year>;<volume>81</volume>(<issue>3</issue>):<fpage>559</fpage>-<lpage>575</lpage>. doi:<pub-id pub-id-type="doi">10.1086/519795</pub-id>
<?supplied-pmid 17701901?><pub-id pub-id-type="pmid">17701901</pub-id></mixed-citation></ref><ref id="zoi190436r38"><label>38</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Dupont</surname><given-names>WD</given-names></name>, <name name-style="western"><surname>Plummer</surname><given-names>WD</given-names><suffix>Jr</suffix></name></person-group>
<article-title>Power and sample size calculations: a review and computer program</article-title>. <source>Control Clin Trials</source>. <year>1990</year>;<volume>11</volume>(<issue>2</issue>):<fpage>116</fpage>-<lpage>128</lpage>. doi:<pub-id pub-id-type="doi">10.1016/0197-2456(90)90005-M</pub-id>
<?supplied-pmid 2161310?><pub-id pub-id-type="pmid">2161310</pub-id></mixed-citation></ref><ref id="zoi190436r39"><label>39</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Topchiy</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Cirstea</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kong</surname><given-names>HJ</given-names></name>, <etal/></person-group>
<article-title>Lipopolysaccharide is cleared from the circulation by hepatocytes via the low density lipoprotein receptor</article-title>. <source>PLoS One</source>. <year>2016</year>;<volume>11</volume>(<issue>5</issue>):<fpage>e0155030</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0155030</pub-id>
<?supplied-pmid 27171436?><pub-id pub-id-type="pmid">27171436</pub-id></mixed-citation></ref><ref id="zoi190436r40"><label>40</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Dwivedi</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>Grin</surname><given-names>PM</given-names></name>, <name name-style="western"><surname>Khan</surname><given-names>M</given-names></name>, <etal/></person-group>
<article-title>Differential expression of <italic>PCSK9</italic> modulates infection, inflammation, and coagulation in a murine model of sepsis</article-title>. <source>Shock</source>. <year>2016</year>;<volume>46</volume>(<issue>6</issue>):<fpage>672</fpage>-<lpage>680</lpage>. doi:<pub-id pub-id-type="doi">10.1097/SHK.0000000000000682</pub-id>
<?supplied-pmid 27405064?><pub-id pub-id-type="pmid">27405064</pub-id></mixed-citation></ref><ref id="zoi190436r41"><label>41</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Berger</surname><given-names>J-M</given-names></name>, <name name-style="western"><surname>Loza Valdes</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Gromada</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Anderson</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Horton</surname><given-names>JD</given-names></name></person-group>
<article-title>Inhibition of PCSK9 does not improve lipopolysaccharide-induced mortality in mice</article-title>. <source>J Lipid Res</source>. <year>2017</year>;<volume>58</volume>(<issue>8</issue>):<fpage>1661</fpage>-<lpage>1669</lpage>. doi:<pub-id pub-id-type="doi">10.1194/jlr.M076844</pub-id>
<?supplied-pmid 28600283?><pub-id pub-id-type="pmid">28600283</pub-id></mixed-citation></ref><ref id="zoi190436r42"><label>42</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Walley</surname><given-names>KR</given-names></name>, <name name-style="western"><surname>Boyd</surname><given-names>JH</given-names></name>, <name name-style="western"><surname>Kong</surname><given-names>HJ</given-names></name>, <name name-style="western"><surname>Russell</surname><given-names>JA</given-names></name></person-group>
<article-title>Low low-density lipoprotein levels are associated with, but do not causally contribute to, increased mortality in sepsis</article-title>. <source>Crit Care Med</source>. <year>2019</year>;<volume>47</volume>(<issue>3</issue>):<fpage>463</fpage>-<lpage>466</lpage>. doi:<pub-id pub-id-type="doi">10.1097/CCM.0000000000003551</pub-id>
<?supplied-pmid 30394916?><pub-id pub-id-type="pmid">30394916</pub-id></mixed-citation></ref><ref id="zoi190436r43"><label>43</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Boyd</surname><given-names>JH</given-names></name>, <name name-style="western"><surname>Fjell</surname><given-names>CD</given-names></name>, <name name-style="western"><surname>Russell</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Sirounis</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Cirstea</surname><given-names>MS</given-names></name>, <name name-style="western"><surname>Walley</surname><given-names>KR</given-names></name></person-group>
<article-title>Increased plasma PCSK9 levels are associated with reduced endotoxin clearance and the development of acute organ failures during sepsis</article-title>. <source>J Innate Immun</source>. <year>2016</year>;<volume>8</volume>(<issue>2</issue>):<fpage>211</fpage>-<lpage>220</lpage>. doi:<pub-id pub-id-type="doi">10.1159/000442976</pub-id>
<?supplied-pmid 26756586?><pub-id pub-id-type="pmid">26756586</pub-id></mixed-citation></ref><ref id="zoi190436r44"><label>44</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Genga</surname><given-names>KR</given-names></name>, <name name-style="western"><surname>Lo</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Cirstea</surname><given-names>MS</given-names></name>, <etal/></person-group>
<article-title>Impact of <italic>PCSK9</italic> loss-of-function genotype on 1-year mortality and recurrent infection in sepsis survivors</article-title>. <source>EBioMedicine</source>. <year>2018</year>;<volume>38</volume>:<fpage>257</fpage>-<lpage>264</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ebiom.2018.11.032</pub-id>
<?supplied-pmid 30473376?><pub-id pub-id-type="pmid">30473376</pub-id></mixed-citation></ref><ref id="zoi190436r45"><label>45</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Deshpande</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Pasupuleti</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Rothberg</surname><given-names>MB</given-names></name></person-group>
<article-title>Statin therapy and mortality from sepsis: a meta-analysis of randomized trials</article-title>. <source>Am J Med</source>. <year>2015</year>;<volume>128</volume>(<issue>4</issue>):<fpage>410</fpage>-<lpage>417.e1</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.amjmed.2014.10.057</pub-id>
<?supplied-pmid 25526798?><pub-id pub-id-type="pmid">25526798</pub-id></mixed-citation></ref></ref-list><notes notes-type="supplementary-material" id="note-ZOI190436-1"><supplementary-material content-type="local-data" id="note-ZOI190436-1-s"><label>Supplement.</label><caption><p><bold>eMethods.</bold> Cohort Identification and Power Calculations</p><p><bold>eTable 1.</bold> Event Counts in Each Analysis</p><p><bold>eTable 2.</bold> Event Counts by Genotypes</p><p><bold>eTable 3.</bold> Associations Between Comorbidity Score and Sepsis and Related Outcomes</p><p><bold>eTable 4.</bold> SNPs Included in <italic>PCSK9</italic> Genetic Risk Score</p><p><bold>eTable 5.</bold> SNPs Included in Estimated <italic>PCSK9</italic> Expression</p><p><bold>eTable 6.</bold> Associations Between Median Measured LDL-C Levels and 4 Functional <italic>PCSK9</italic> Variants</p><p><bold>eTable 7.</bold> Associations Between Median Measured LDL-C Levels and <italic>PCSK9</italic> GRS</p><p><bold>eTable 8.</bold> Associations Between Median Measured LDL-C Levels and <italic>PCSK9</italic> Expression</p><p><bold>eTable 9.</bold> Associations Between <italic>PCSK9</italic> Candidate SNPs and Sepsis and Related Adverse Outcomes</p><p><bold>eTable 10.</bold> Associations Between <italic>PCSK9</italic> GRS and Sepsis and Related Adverse Outcomes</p><p><bold>eTable 11.</bold> Associations Between Genetically Estimated <italic>PCSK9</italic> Expression Tertiles and Sepsis and Related Adverse Outcomes</p><p><bold>eFigure.</bold> Algorithm to Identify Sepsis Within Infection Cohort</p><p><bold>eReferences.</bold></p></caption><media xlink:href="jamanetwopen-2-e1911130-s001.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></notes></back></article><?release-delay 0|0?>